GTx has established strategic collaborations that serve to strengthen and deepen our R&D and expedite commercialization of our product candidates. These relationships build upon our expertise in urology and oncology and in the discovery and development of small molecule selective receptor modulators. They provide GTx with the opportunity for near-term revenue while reducing the risks associated with the failure of a particular product development program. Partners also help GTx extend our reach globally and into general and specialty medical fields beyond our own established relationships in urology and oncology.
Current licenses and collaborative relationships include:
GTx Has Licensed Toremifene and FARESTON® from Orion Pharma
In March 2000, GTx acquired the license and supply rights from Orion to develop and commercialize products containing toremifene. In December 2004, GTx replaced the original contract with an amended and restated license and supply agreement to purchase specified Fareston related assets.